Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
ConditionChronic Lymphocytic Leukemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
Eligibility criteria
Qualifiers
Age ≥18 years.
Confirmed diagnosis of CLL.
Newly prescribed acalabrutinib monotherapy within the previous four weeks preceding study enrolment. Monotherapy is defined as acalabrutinib prescribes without concomitant administration (or planned initiation) of other anti-leukemic agents (e.g. obinutuzumab, venetoclax, bendamustine) within ± 30 days of acalabrutinib initiation.
Treatment-naïve or R/R CLL.
Disqualifiers
Patients not satisfying any of the inclusion criteria.
Prior treatment with any BTK inhibitor.
Participation in other ongoing clinical trials.
Pregnant or breastfeeding females
Trial design
Treatments tested in this trial
- Not listed
Trial groups
50 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov